Cowage Seed (Mucuna pruriens): A Comprehensive Reference
1. Identity: Botanical Names, Natural Source, and Common Forms
1.1 Taxonomy and Botanical Classification
Mucuna pruriens (L.) DC. belongs to the family Fabaceae and is commonly known as velvet bean, cow witch, and cow hage due to its morphology, phytochemical constituents, traditional uses, medicinal values, and pharmacological activities. It is a tropical legume native to Africa and tropical Asia and widely naturalized and cultivated. Its English common names include monkey tamarind, velvet bean, Bengal velvet bean, Florida velvet bean, Mauritius velvet bean, Yokohama velvet bean, cowage, cowitch, lacuna bean, and Lyon bean.
The accepted scientific name is Mucuna pruriens (L.) DC., family Fabaceae. Its standardized common name in English is velvet bean, and its Ayurvedic names include atmagupta and kapikacchu. The word kapikacchu in Sanskrit roughly translates to "one who itches like a monkey," while atmagupta means "secret self," hinting at the therapeutic value of the seed concealed within the allergenic seedpod.
1.2 Plant Description
Mucuna pruriens is an annual climbing shrub with long vines that can reach over 15 metres (50 feet) in length. When the plant is young, it is almost completely covered with fuzzy hairs, but when older, it is almost completely free of hairs. The plant is a long, slender climber with fleshy fruits containing three to six seeds. Its seeds are fawnish-brown, ellipsoid, and small. The plant is notorious for the extreme itchiness it produces on contact, particularly with the young foliage and the seed pods. It also produces many medium-sized red swollen bumps on the skin with the itching.
1.3 Botanical Varieties
There are four botanical varieties of M. pruriens: M. pruriens var. utilis is the cultivated variety that does not itch; M. pruriens var. pruriens ("pica pica") has urticating hairs that contain the irritating compound mucanain; M. pruriens var. hirsuta, from India; and M. pruriens var. sericophylla, from the Philippines.
1.4 Geographic Distribution
M. pruriens is native to India and Southeast Asia, but is now widely distributed in the tropics. It is widespread over most of the Indian subcontinent and found in forms of bushes, hedges, and in dry deciduous low forests throughout the plains of India.
1.5 Common Forms and Preparations
There are traditional uses for the root and the trichomes (the irritating hairs themselves), but the large, dense seeds found within the pods offer the powerful rejuvenating qualities that this herb is best known for. It is these nourishing seeds that are most often used.
Cowage seed is encountered commercially in several forms:
- Raw or roasted seed powder: The whole dried seed ground into a powder, with an L-DOPA content approximately reflecting the natural range of the plant.
- Standardized extracts: The L-DOPA content in raw, unstandardized velvet bean powder typically ranges from approximately 3% to 7% of its total dry weight. In contrast, most modern dietary supplements are made from standardized extracts, which are concentrated to ensure a consistent level of L-DOPA per serving. These standardized products often contain 10%, 15%, or 20% L-DOPA, making them far more potent than raw powder.
- Capsules and tablets: Encapsulated seed powder or extract, the most common retail supplement form.
- Traditional decoctions: Traditionally, Ayurvedic practitioners use the dried seeds and occasionally the root extract of Mucuna pruriens to prepare decoctions and powders, focusing on the seed's L-DOPA and other bioactives for therapeutic formulations.
- Anupana preparations: In traditional Ayurveda, Mucuna is taken in the anupana (activator/catalyst) of warmed milk with honey.
Levodopa stability is a critical consideration in any preparation. The stability of L-dopa is a great concern in pharmaceutical product development. At room temperature and at uncontrolled pH, L-dopa levels significantly decline within a 48-hour period. Additionally, the final concentration of constituents in M. pruriens preparations is dependent on the method of extraction, for example with alcohol or water, and the applied conditions. Variability in concentration can also be caused by geographical origin and genetic nature between M. pruriens varieties.
2. Traditional and Historical Use
2.1 Ayurvedic Medicine (India)
The history of Mucuna pruriens in therapeutic use can be traced back to the classical Samhita period (circa 1500 BCE–400 CE), where it was recognized for its potent restorative and vitalizing properties. In the Charaka Samhita, one of the oldest and most authoritative texts on Ayurveda, the plant is mentioned under various categories. In Ayurveda, Kapikachhu is primarily celebrated for its profound effects in Vajikarana (aphrodisiac and male reproductive health), management of Kampavata (neuro-motor disorders akin to Parkinson's disease), and as a Rasayana (rejuvenative tonic).
Ancient Ayurvedic texts like the Charaka Samhita and Sushruta Samhita mention Kapikacchu under categories of Vata-balancing Rasayanas (rejuvenators) and Medhya Rasayanas (nootropic tonics).
In the classical Ayurvedic framework, the seed is understood through its elemental properties: the primary tastes are Madhura (sweet) and Tikta (bitter). The sweet taste is responsible for its nourishing, tonic, and tissue-building (Brimhana) properties, while the bitter taste contributes to its detoxifying character. The main qualities are Guru (heavy) and Snigdha (unctuous, oily).
Different parts of the plant are used in Ayurvedic research since ancient period to cure many diseases such as bone fractures, cough, dog-bite, madness, pain, pleuritis, ring worm, and scorpion sting. Seeds are used in snakebite, sexual debility, cough, tuberculosis, impotence, rheumatic disorders, muscular pain, gonorrhea, sterility, gout, delirium, dysmenorrhea, diabetes, and cancer.
In Ayurveda, Mucuna is used from ancient times for various neurological and general debility problems. It is used in dysfunction of all three doshas — Vata, Pitta, and Kapha — especially in aggravated Vata and Pitta.
2.2 Unani (Greco-Arabic) Medicine
The seed of Mucuna, commonly known in the west as velvet beans or cowhage, is an important herb in the ancient Indian Ayurvedic system of medicine and Unani Tibb (Greco-Arabic) medicine, and has been worked with medicinally for at least 2000 years. Mucuna pruriens seeds are widely used for treating male sexual dysfunction in Unani Medicine, the traditional system of medicine of the Indo-Pakistani subcontinent. Mucuna pruriens seeds are also proven to be effective in profuse menstruation and in paralysis and have been used since ancient times in the treatment of nervous disorders.
2.3 Traditional Uses in Africa and the Wider Tropics
The tropical legume Mucuna pruriens is indigenous to Africa and tropical Asia, but has become widely naturalized and cultivated throughout the world. The plant's presence across sub-Saharan Africa has led to parallel ethnobotanical traditions employing it for neurological and reproductive complaints, as evidenced by recent clinical research specifically targeting African populations with Parkinson's disease.
2.4 Preparations Used Historically
Seeds of Mucuna pruriens are prescribed in the form of powder in the treatment of leucorrhoea, spermatorrhoea, and in cases requiring aphrodisiac action. Seed powder including seed coat is an ingredient of the Ayurvedic drug Vita-ex, given as an aphrodisiac. Its energizing restorative nature is traditionally used with other adaptogens and rasayana (rejuvenative) herbs like Ashwagandha, Brahmi, Shatavari, Bacopa, and Amalaki.
3. Key Constituents and Active Compounds
3.1 Primary Phytochemical: L-DOPA (Levodopa)
The seeds of M. pruriens are renowned for their high concentration of L-3,4-dihydroxyphenylalanine (L-DOPA), a metabolic precursor of dopamine. The seeds of the plant contain about 3.1–6.1% L-DOPA. It has been observed that Mucuna species growing near the equator have higher levels of levodopa present than plants far away from the equator.
3.2 Alkaloids and Nitrogenous Compounds
Levodopa (L-dopa) is the pharmacologically important chemical constituent mainly found in the seeds of M. pruriens, in addition to the presence of many more constituents such as tryptamine, 5-hydroxytryptamine, mucunine, mucunadine, prurienine, and prurieninine. Duke's Phytochemical and Ethnobotanical Database describes diversified chemical constituents in Mucuna seeds including 5-hydroxytryptamine, 5-methoxy-N,N-dimethyltryptamine-N-oxide, 6-methoxyharman, arachidic acid, arginine, beta-carboline, beta-sitosterol, bufotenine, choline, gallic acid, glutamic acid, glutathione, indole-3-alkylamine, linoleic acid, mucunadine, mucunain, mucynine, myristic acid, N,N-dimethyltryptamine, niacin, nicotine, oleic acid, and palmitic acid.
3.3 Phenolic Compounds and Flavonoids
The neuroprotective effects, particularly important in Parkinson's disease, appear to result from the synergistic action of L-DOPA, phenolic antioxidants such as flavonoids (quercetin and kaempferol derivatives, catechins, and rutin), phenolic acids (gallic, caffeic, ferulic, p-coumaric, and chlorogenic), and other neuroactive metabolites. HPLC analysis of M. pruriens seed extract has shown L-DOPA, gallic acid, phytic acid, quercetin, and catechin equivalents as the major components.
3.4 Nutritional and Other Constituents
The seeds are reported to have diversified nutritionally and pharmacologically valued chemical constituents including proteins, minerals, vitamins (niacin, ascorbic acid), amino acids (glutamic acid, aspartic acid, serine, threonine, proline, alanine, glycine, valine, cystine, methionine, isoleucine, leucine, tyrosine, phenylalanine, tryptophan, lysine, histidine, and arginine), glutathione, lecithin, gallic acid, fatty acids (palmitic, oleic, stearic, linoleic, linolenic, and behenic acid), and beta-sitosterol.
Analysis of air-dried seeds of M. pruriens showed the presence of several constituents: phenolics, trypsin inhibitors, saponins, phytic acid, levodopa, raffinose, stachyose, and verbascose.
M. pruriens possesses a high protein concentration (23%–25%) and good digestibility, rendering it a valuable alternative food source.
Seeds also contain several anti-nutrients. Like most legumes, Mucuna pruriens contains various antinutrients that limit its nutritional quality, including tannins (which may bind to proteins and reduce their digestion), trypsin inhibitors (which reduce digestive enzyme activity), phytates (which can bind to minerals and block their absorption in the gut), cyanogenic glycosides, lectins, and oligosaccharides (FODMAPs, which can cause flatulence).
There is evidence that the canonical amino acids and L-DOPA precursors L-phenylalanine (L-Phe) and L-tyrosine (L-Tyr) can increase dopamine synthesis and also protect against the mistaken incorporation of L-DOPA into proteins during protein synthesis.
4. Mechanisms of Action
4.1 Dopaminergic Pathway
From a pharmacological point of view, the high content of L-DOPA is a key factor distinguishing M. pruriens from other medicinal plants. The presence of this direct precursor of dopamine provides a biological basis for the use of the plant in diseases characterized by dopamine deficiency. Levodopa, as a dopamine precursor, remains the cornerstone of PD pharmacotherapy because it replenishes the deficient dopamine caused by neuronal loss. When administered orally, L-DOPA crosses the blood–brain barrier and is converted into dopamine in the brain, improving motor symptoms such as tremor, rigidity, and bradykinesia.
4.2 Potential Superiority Over Isolated L-DOPA
Preparations of Mucuna pruriens that contain L-DOPA may be 2 to 3 times more potent than an equivalent dose of isolated L-DOPA (when not combined with carbidopa). This higher potency could be due to components in Mucuna pruriens acting as dopamine decarboxylase inhibitors, preventing the conversion of L-DOPA into dopamine in peripheral tissues, thereby allowing more L-DOPA to reach the brain. It could also be due to other components in Mucuna pruriens having anti-Parkinsonian properties in their own right.
4.3 Antioxidant and Anti-inflammatory Mechanisms
Studies have demonstrated that its extracts exert antioxidant effects, preserve mitochondrial function, and improve motor behavior. For instance, acidic extracts rich in phenolics and L-dopa have shown significant neuroprotective properties, while cotyledon extracts appear to restore neurotransmitter balance in the nigrostriatal pathway. Additionally, M. pruriens has been found to enhance mitochondrial complex I activity and reduce oxidative stress through the actions of its phytoestrogens and cofactors.
M. pruriens extract treatment containing L-DOPA and a mixture of rich novel phytochemicals significantly alleviates MPTP-induced neurotoxicity by NF-κB and pAkt pathway. The findings indicate that M. pruriens extract ameliorated MPTP-induced neuroinflammation, restored the biochemical and behavioral abnormalities in PD mouse models, and thus provided a scientific basis for its traditional claim.
4.4 Cholinergic Modulation
Research results suggest that M. pruriens seed aqueous extract was probably able to modulate the cholinergic system and reduce L-dopa-induced dyskinesia and movement disorders resulting from L-dopa treatment. The study demonstrated the neuroprotective activity of M. pruriens seed extract, which may imply therapeutic effects in various nervous system disorders including Parkinson's disease.
4.5 Hypothalamic-Pituitary-Gonadal (HPG) Axis and Male Fertility
Treatment with M. pruriens significantly improved testosterone (T), LH, dopamine, adrenaline, and noradrenaline levels in infertile men and reduced levels of FSH and PRL. Sperm count and motility were significantly recovered in infertile men after treatment. Treatment with M. pruriens regulates steroidogenesis and improves semen quality in infertile men.
Evidence supports the plant's role in male reproductive health, with improvements in hormonal profile and sperm parameters attributed to catecholamine restoration and antioxidant effects.
4.6 Antioxidant Activity in Seminal Plasma
Treatment with M. pruriens significantly inhibited lipid peroxidation, elevated spermatogenesis, and improved sperm motility. Treatment also recovered the levels of total lipids, triglycerides, cholesterol, phospholipids, and vitamin A, C, and other compounds in seminal plasma.
4.7 ACE Inhibition and Antihypertensive Effects
In the search for safe and effective lead molecules from natural sources, M. pruriens L. seeds were utilized for exploring antihypertensive potential. Traditionally, it is used as a diuretic and hypotensive. Phytochemical analysis by spectroscopic techniques revealed the presence of known compounds like genistein, ursolic acid, and L-DOPA from the ethyl acetate and water fractions, respectively, which are candidate compounds for ACE inhibitory activity. This evidence, however, comes primarily from animal models.
5. Scientific Evidence by Area of Use
5.1 Parkinson's Disease
Background
Mucuna pruriens has attracted increasing research attention as an alternative treatment for Parkinson's disease. It contains a significant amount of L-dopa (4%–6%), the primary active component of conventional levodopa (LD) therapy — the gold standard treatment for PD. M. pruriens is also recognized for its anti-inflammatory, antioxidant, antiapoptotic, and antiparkinsonian properties, which collectively suggest therapeutic benefits for individuals with PD.
Systematic Review (2024)
A comprehensive systematic review searched PubMed, Embase, and Web of Science for clinical trials published up to February 2024. Studies comparing M. pruriens to conventional LD were included, and quality assessment was performed. Out of 466 articles identified, 5 clinical trials involving a total of 108 participants (mean age: 60 years) were included.
All included trials assessed changes in both voluntary and involuntary motor responses following M. pruriens treatment. In the 1995 multicenter trial, UPDRS-III scores improved significantly, decreasing from 18.2 to 9.8 overall. This improvement was observed after M. pruriens administration in both LD-naïve patients and those previously treated with LD/CD.
Double-Blind Randomized Controlled Crossover Study (2017)
Single-dose M. pruriens intake met all noninferiority efficacy and safety outcome measures in comparison to dispersible levodopa/benserazide. Clinical effects of high-dose MP were similar to levodopa alone at the same dose, with a more favorable tolerability profile. Importantly, its use has not been associated with the long-term complications commonly observed with synthetic LD.
16-Week Crossover Pilot Study
Thousands of individuals with Parkinson's disease in low-income countries have limited access to marketed levodopa preparations. Mucuna pruriens may be a sustainable alternative therapy for indigent patients. Single-dose intake of MP proved noninferior to marketed levodopa preparations. Fourteen PD patients with motor fluctuations and dyskinesias received MP powder (obtained from roasted seeds) and marketed levodopa/carbidopa (LD/CD) in a randomized order and crossover design over a 16-week period.
12-Month Multicenter Randomized Controlled Trial (Sub-Saharan Africa, 2026)
This trial aimed to demonstrate the non-inferiority of long-term intake of MP powder compared to standard levodopa plus dopa-decarboxylase inhibitor (LD + DDCI). In this 12-month, multicenter, randomized, open-label phase 2 trial, thirty-two untreated PD patients received levodopa monotherapy with MP powder — derived from roasted seeds without pharmacological processing — or standard LD + DDCI. Dosing was adjusted for body weight and disease stage, with MP doses further calibrated to account for the absence of a DDCI. MP powder improved quality of life, motor and non-motor symptoms over 12 months, demonstrating similar outcomes to LD + DDCI on all endpoints. Adverse events were more frequent with MP (56% vs. 37.5%), though the difference was not statistically significant. Most were mild, with only 12.5% leading to discontinuation.
Evidence Characterization for Parkinson's Disease
The evidence base for cowage seed in Parkinson's disease is the best-developed among its uses. Multiple randomized and crossover clinical trials consistently demonstrate noninferiority to standard pharmaceutical levodopa preparations for short-term motor endpoints. To confirm long-term safety and efficacy, larger international multicenter, double-blind trials with extended follow-up (e.g., 24–36 months) and ethnically diverse cohorts are needed. The total number of clinical trial participants across all trials remains small (108 total across the systematic review), and the absence of long-term, large-scale, double-blind trials means that caution is warranted in drawing definitive conclusions.
5.2 Male Infertility and Reproductive Health
Clinical Study — Semen Quality in Stressed Infertile Men (2008)
The investigation was undertaken to assess the role of Mucuna pruriens in infertile men who were under psychological stress. The study included 60 subjects who were undergoing infertility screening and were found to be suffering from psychological stress, assessed on the basis of a questionnaire and elevated serum cortisol levels. Age-matched 60 healthy men having normal semen parameters served as controls. Infertile subjects were administered with M. pruriens seed powder (5 g day−1) orally. Semen samples were collected before starting treatment and after 3 months of treatment. The results demonstrated decreased sperm count and motility in subjects who were under psychological stress.
Clinical Study — Biochemical Parameters in Infertile Men
A prospective study was conducted at King George's Medical University, Lucknow, India, involving 60 normal healthy fertile men (controls) and 60 men undergoing infertility screening. Treatment with M. pruriens significantly inhibited lipid peroxidation, elevated spermatogenesis, and improved sperm motility. Treatment also recovered the levels of total lipids, triglycerides, cholesterol, phospholipids, and vitamin A, C, and related compounds.
Clinical Study — Hypothalamic-Pituitary-Gonadal Axis (2008)
A prospective study enrolled 75 normal healthy fertile men (controls) and 75 men undergoing infertility screening. Decreased sperm count and motility were seen in infertile subjects. Serum T and LH levels, as well as seminal plasma and blood levels of dopamine, adrenaline, and noradrenaline, were also decreased in all groups of infertile men. Treatment with Mucuna pruriens seed powder helped fight stress-mediated poor semen quality and acted as a restorative and invigorator tonic or aphrodisiac in infertile subjects. The study reported successful treatment of 70% of infertile individuals.
Clinical evidence — particularly from clinical administration of M. pruriens seed powder at a dose of 5 g/day, mixed with milk, for a duration of three months — indicates its role in enhancing seminal fructose levels and improving semen quality. It also increases sperm concentration, motility, vitality, and morphology.
Evidence Characterization for Male Infertility
Human clinical studies on male infertility consistently show improvements in sperm parameters and hormonal profiles. However, these studies are mostly prospective, uncontrolled or poorly controlled, and conducted at single centers with predominantly South Asian populations. In light of the encouraging results, there is a need for further in-depth studies to investigate the role of M. pruriens and its biologically active compounds in increasing the fertilizing potential in infertile men. Overall, the evidence is promising but preliminary, and conclusions should not be extrapolated without larger randomized controlled trials.
5.3 Neuroprotection Beyond Parkinson's Disease
While Mucuna is a well-known natural source of levodopa, published studies suggest that other bioactive compounds may also be responsible for its anti-PD effects. To investigate this hypothesis, an L-dopa reduced (<0.1%) M. pruriens seeds extract (MPE) was prepared and evaluated for its anti-PD effects in cellular (murine BV-2 microglia and human SH-SY5Y neuroblastoma cells), Caenorhabditis elegans, and Drosophila melanogaster models. This research suggests neuroprotective phytochemicals beyond L-DOPA may play a role, though this work remains preclinical (cell and animal models only).
The presence of a large amount of L-dopa, alkaloids, and a minor amount of 5-hydroxytryptamine have been reported in the seeds. The powder of the seeds is clinically used for the management of hyperprolactinemia and Parkinson's disease, as it contains a high concentration of L-dopa. The neuroprotective action of seeds of M. pruriens has been shown to be due to restoration of the endogenous monoamine contents, including dopamine, in the substantia nigra.
5.4 Antidepressant Effects
The potential antidepressant properties of cowage seed have been investigated in preclinical models. Multiple lines of investigation have explored the role of dopaminergic systems in mental depression. The seed of Mucuna pruriens is well-known for its dopaminergic action and has several therapeutic applications in folk medicine, including managing Parkinsonism. Studies demonstrating antidepressant effects in experimental models are animal-based and do not constitute human clinical evidence. Extrapolation to humans would be premature.
5.5 Blood Glucose Regulation
Regenerative effects on pancreatic tissue are primarily attributed to the antioxidant activities of MP's bioactive compounds, which mitigate oxidative damage and facilitate cellular recovery. Despite extensive preclinical evidence supporting the antidiabetic potential of MP, most studies have independently evaluated either its hypoglycemic effects or histological improvements without integrating both outcomes systematically. Previous studies have predominantly focused on short-term glycemic outcomes, often overlooking the influence of treatment duration and dosage on long-term therapeutic potential. Furthermore, the heterogeneity in experimental designs, including variations in animal models, extraction methods, and diabetes induction protocols, has complicated the establishment of standardized therapeutic guidelines. This area currently lacks human clinical evidence.
5.6 Blood Pressure
Research on the antihypertensive activity of cowage seed constituents, particularly ACE-inhibitory effects of isolated compounds such as genistein and ursolic acid, remains at the in vitro and animal study level. Seeds were utilized for exploring antihypertensive potential, and traditionally, M. pruriens is used as a diuretic and hypotensive. No human clinical trials establishing antihypertensive efficacy have been identified in the peer-reviewed literature at this time.
6. Body Systems and Health Areas of Association
- Neurological system: Parkinson's disease (most well-studied), general neuroprotection, hyperprolactinemia, stress-related neurochemical dysregulation, and historically "Kampavata" (tremor disorders).
- Reproductive system (male): Sperm count, motility, and morphology; testosterone and LH restoration; management of oligozoospermia, asthenozoospermia, and stress-induced infertility.
- Endocrine system: Modulation of prolactin (PRL), FSH, LH, testosterone; blood glucose regulation (preclinical).
- Cardiovascular system: Potential antihypertensive and ACE-inhibitory effects (preclinical only).
- Musculoskeletal system: Traditional uses for rheumatic disorders, muscular pain (no rigorous clinical evidence).
- Psychological / mood: Dopaminergic antidepressant effects in animal models; traditional use as a general "nervine tonic" and adaptogen.
7. Dosage Forms and Dosages Reported in Studies
Most trials that investigated the effects of Mucuna pruriens on symptoms of Parkinson's disease or male infertility have used daily doses ranging between 5 and 45 grams of adequately prepared seed powder, corresponding to approximately 200 mg to 1,500 mg of L-DOPA.
Specific dosages from individual studies include:
- Male infertility studies: Infertile subjects were administered M. pruriens seed powder (5 g day−1) orally for a period of 3 months.
- Parkinson's disease crossover study: Fourteen PD patients with motor fluctuations and dyskinesias received MP powder (obtained from roasted seeds) and marketed levodopa/carbidopa in a randomized order and crossover design over a 16-week period.
- 12-month sub-Saharan Africa RCT: Thirty-two untreated PD patients received levodopa monotherapy with MP powder derived from roasted seeds without pharmacological processing or standard LD + DDCI. Dosing was adjusted for body weight and disease stage, with MP doses further calibrated to account for the absence of a DDCI.
Regarding standardized commercial extracts, standardized products often contain 10%, 15%, or 20% L-DOPA. A 15% standardized extract means that a 1,000 milligram (1 gram) dose of the powder delivers 150 milligrams of L-DOPA. This calculation is essential because dosing is ultimately based on the target quantity of L-DOPA, not the total powder weight, especially when switching between products.
It is important to note that no universally established or consensus therapeutic dose exists for cowage seed as a dietary supplement outside of clinical trial protocols. Very little scientific information about Mucuna pruriens is publicly available. Accordingly, it is not possible to determine a safe dose.
8. Safety Considerations and Drug Interactions
8.1 Levodopa Content as a Safety Determinant
One of the substances in Mucuna pruriens seeds is levodopa. Levodopa is used as a medicine in the treatment of Parkinson's disease. The quantity of levodopa ingested through food supplements containing Mucuna pruriens is comparable to or higher than the quantity of levodopa ingested by people with Parkinson's disease when they first start using the medicine. The side effects of this medicine, such as gastrointestinal symptoms, involuntary movement (dyskinesia), and psychological symptoms, can therefore also occur when using nutritional supplements containing Mucuna pruriens.
8.2 Gastrointestinal Side Effects
In a 12-month clinical trial, adverse events were more frequent with MP powder (56% vs. 37.5%), though the difference was not statistically significant. In a study of patients with Parkinson's disease, a derivative of Mucuna pruriens caused minor adverse effects, which were mainly gastrointestinal in nature.
8.3 Neuropsychiatric Adverse Events
Isolated cases of acute toxic psychosis have been reported, probably due to levodopa content. Therefore, as with Sinemet and Madopar, its use should be avoided in patients with psychosis or schizophrenia.
8.4 Potential Organ Toxicity
There are indications that Mucuna pruriens can have negative effects on the liver, kidneys, and the development of unborn children. As a precaution, RIVM therefore advises not to use food supplements containing Mucuna pruriens during pregnancy and breastfeeding, or in case of liver or kidney problems.
8.5 Contact Hazard
Direct contact with Mucuna pruriens pods can cause severe itching and rashes, and consuming raw beans and seeds may cause poisoning and toxicity. This is due to the urticating trichomes (mucunain) present on the pod surface.
8.6 Product Quality and Label Accuracy Concerns
The claimed L-DOPA content ranged from 25 to 250 mg per dose for the six commercial products tested. HPLC analysis revealed that only two of the products had L-DOPA values close to the value claimed. The remaining products contained considerably less L-DOPA, with less than 10% of the labeled amount in two cases. Certificates of analysis suggested that not all manufacturers routinely measure L-DOPA content of their mucuna product. Four of six products examined showed a large discrepancy between label claim and L-DOPA content.
Quality testing shows that some supplements have inconsistent amounts of levodopa, sometimes up to 22 times higher than labeled. Some products contained either no levodopa or drastically varying amounts, from 2 to 241 mg per serving.
8.7 Drug Interactions
Because Mucuna pruriens contains levodopa (a prescription medication), it may have similar drug interactions to levodopa. However, the exact implications of these interactions are unknown due to limited research.
Key documented or theorized interactions include:
- Conventional levodopa medications: Mucuna pruriens should not be used in conjunction with medications that contain L-DOPA; combining the two could potentially result in excessively high dopamine levels, leading to adverse effects.
- MAO Inhibitors (MAOIs): Using levodopa with non-selective MAOIs can cause a hypertensive crisis. Some antidepressants and anti-Parkinson's drugs (Monoamine Oxidase Inhibitors or MAOI) should be avoided; the use of both may dangerously increase dopamine levels and cause very high blood pressure.
- Antihypertensive drugs: The supplement can interact with antihypertensive drugs because it has the potential to lower blood pressure, risking hypotension when taken concurrently. Antihypertensives, antidepressants, sedatives, and alpha blockers (used in prostate therapy) may promote orthostatic hypotension.
- Antidiabetic drugs: The potential blood-glucose-lowering properties of Mucuna pruriens mean that it could interact with diabetes medications.
- Antipsychotics (D2 antagonists): Some antipsychotics (D2 antagonists) can reduce the effects of Mucuna pruriens.
- Substances inhibiting levodopa absorption: Substances which inhibit the absorption of levodopa include spiramycin, salts of iron, and antacids (dyspepsia).
- Melanoma: Individuals with melanoma should avoid the supplement, as L-DOPA is a precursor to melanin and could potentially accelerate cancer growth.
8.8 Pregnancy and Breastfeeding
Supplementation should be avoided during pregnancy and breastfeeding because safety evidence is limited. The safety of Mucuna pruriens has not been established in children, pregnant, or breastfeeding women.
References
Go back